Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tranexamic acid to reduce postoperative bleeding in oncologic-reconstructive breast surgery
2018-000910-39Phase 4Active
- Sponsor
- Azienda Ospedaliero-Universitaria di Udine
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of tranexamic acid in breast cancer, postoperative hematoma and Breast hematoma (2 arms), sponsored by Azienda Ospedaliero-Universitaria di Udine. Primary endpoint: Reduction in postoperative drain output within 36 hours. Started Sep 2021; status: active.
02
Drugs
tranexamic acid
03
Conditions
breast cancerpostoperative hematomaBreast hematoma
Beyond the preview
Go deeper on 2018-000910-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000910-39.